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Summary
Mild hyperhomocysteinaemia is a major risk factor
for vascular disease and neural tube defects (NTDs),
conferring an approximately three-fold relative risk
for each condition. It has several possible causes:
heterozygosity for rare loss of function mutations in
the genes for 5,10-methylene tetrahydrofolate
reductase (MTHFR) or cystathionine-/?-synthase
(CBS); dietary insufficiency of vitamin co-factors B6,
B12 or folates; or homozygosity for a common 'ther-
molabile' mutation in the MTHFR gene which has
also been associated with vascular disease and
NTDs. We quantified the contribution of the ther-
molabile mutation to the hyperhomocysteinaemic
phenotype in a working male population (625 indi-
viduals). Serum folate and vitamin B12 concentra-
tions were also measured and their relationship
with homocysteine status and MTHFR genotype
assessed. The homozygous thermolabile genotype
occurred in 48.4, 35.5, and 23.4% of the top 5,10,
and 20% of individuals (respectively) ranked by
plasma homocysteine levels, compared with a fre-
quency of 11.5% in the study population as a whole,
establishing that the mutation is a major determinant
of homocysteine levels at the upper end of the
range. Serum folate concentrations also varied with
genotype, being lowest in thermolabile homozy-
gotes. The MTHFR thermolabile genotype should be
considered when population studies are designed
to determine the effective homocysteine-lowering
dose of dietary folate supplements, and when
prophylactic doses of folate are recommended for
individuals.
Introduction
Mild hyperhomocysteinaemia is now recognized as
an important risk factor for coronary artery disease
(CAD),1'2 peripheral vascular disease,3'4 cerebrovas-
cular disease4"6 and recurrent venous thrombosis.7
Elevated maternal levels of homocysteine have
recently been associated with the occurrence of
NTDs.8
Homocysteine is an unstable thiol amino acid
generated solely as a product of transmethylation
reactions which consume S-adenosyl methionine
(SAM). It is either used to regenerate SAM, in which
case it is initially remethylated to methionine by the
vitamin-B12-dependent enzyme methionine syn-
thase, using 5-methyl tetrahydrofolate as the methyl
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Figure 1. The production of homocysteine in methionine metabolism and the involvement of MTHFR. Arrows in bold
represent points at which genetic defects in the enzyme or in co-factor biosynthesis are known to cause elevated
homocysteine.
donor, or disposed of by the transsulphuration path-
way in which the initial step is its condensation with
serine to form the thioether cystathionine through
the action of the vitamin-B6-dependent enzyme
cystathionine-/?-synthase (CBS) (Figure 1).
Of the enzymes involved in recycling or removing
homocysteine, severe genetic defects resulting in loss
of function are known to affect two: 5,10-methylene
tetrahydrofolate reductase (MTHFR) and cystathion-
ine- jS-synthase (CBS). The genes encoding each of
these two enzymes have been cloned and sequenced,
and several mutations which cause such highly
deficient phenotypes have been identified.
Homozygotes for severe mutations of either the CBS
or MTHFR genes have homocystinuria with associ-
ated premature vascular disease and thromboembol-
ism affecting both large and small arteries and
veins.9'10 Heterozygotes for such severe mutations
have mild hyperhomocysteinaemia; however, these
genotypes are too rare to account for the frequency
of mild hyperhomocysteinaemia observed in the
general population.
MTHFR is a flavoprotein which catalyses the
NADPH-linked reduction of 5,10-methylenetetra-
hydrofolate to 5-methyltetrahydrofolate, the major
circulating form of folate and the methyl donor for
the methioninesynthase-catalysed remethylation of
homocysteine to methionine. A phenotypic variant
of MTHFR with characteristic thermolability after
partial denaturation at 46°C for 5 min11 has been
identified in 5-8% of the healthy population and
shown to give rise to mild hyperhomocysteinaemia
without homocystinuria in healthy controls as well
as CAD patients, in whom it is approximately three
times more common than in healthy controls.12"14
This biochemically-defined thermolabile variant is
the most probable cause of mild hyperhomocysteina-
emia in 28% of hyperhomocysteinaemic vascular
disease patients.15
The cDNA for MTHFR was recently cloned and
sequenced by Goyette ef a/., who identified nine
mutations in classically deficient patients.16'17 In
addition, a C to T transition at nucleotide 677,
resulting in an amino acid change from alanine to
valine, correlated with thermolability; homozygotes
for the mutation had thermolabile MTHFR (defined
by a specific activity of 50% of the normal mean,
and residual activity after heat inactivation of < 3 6 %
of the initial activity), while heterozygotes had inter-
mediate thermolability.18 The mutation resulted in
elevated homocysteine levels irrespective of whether
measurements were made after fasting or methionine
loading. This mutation has subsequently been shown
to confer a 2.9-fold risk of cardiovascular disease in
Ireland (Gallagher ef a/., submitted) and a 3.1-fold
risk of cardiovascular disease in Holland19—figures
which are similar to the relative risk associated with
elevated homocysteine levels.
The frequency of homozygosity for thermolabile
MTHFR in individuals with NTDs is approximately
three times the average in the population,20'21 and
in Ireland 13% of NTDs may be directly attributed
to this factor.20
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Elevated homocysteine is clearly an important risk
indicator for a range of clinical conditions. The
magnitude of risk conferred by the thermolabile
MTHFR genotype is similar to that associated with
elevated homocysteine. To permit a rational assess-
ment of the potential for screening the population to
identify individuals genetically at risk of homocyst-
eine-associated disease, and to devise appropriate
treatments with homocysteine-lowering supplements
such as folic acid, the proportion of individuals who
are hyperhomocysteinaemic due to the thermolabile
MTHFR genotype needs to be determined.
Our study examines the extent to which mild
hyperhomocysteinaemia in a working male popula-
tion is directly attributable to the thermolabile
MTHFR mutation.
by Ubbink et al23 Plasma samples were derivatized
with ammonium 7-fluoro 2-oxa-1,3 diazole-4-sulph-
onate (SBD-F).
Cenotyping for the MTHFR thermolabile mutation
was performed by PCR and H/nfl digestion as in
Frosst et a/.18
Levels of serum folate and vitamin B12 were
measured using an ICN Pharmaceuticals kit.
Statistics were analysed using SPSS for Windows.
Distributions of homocysteine, folate and B12 were
skewed and were logarithmically transformed when
appropriate. Analysis of variance was used to com-
pare mean values between groups (genotypes or
tenths). Relative risk estimates were calculated using
X2 tests with Yates' correction or Fisher's exact
probability test as appropriate.
Methods
Males aged 30-49 from an industrial workforce in
Belfast, comprising both manual and non-manual
workers, were invited to a screening clinic, and after
informed consent for all biochemical and genetic
analyses had been given, a venous blood sample
was taken with minimum haemostasis and anti-
coagulated with EDTA. Individuals who were dia-
betic, had had a general anaesthetic within the
previous 3 months, or were using any form of dietary
supplementation (16.6%) were excluded. A total of
625 men were eligible for inclusion in the present
analysis.
Total homocysteine (free plus protein-bound) was
assayed by high performance liquid chromatography
according to the method of Araki & Sako,22 modified
Results
In our study population, the overall frequencies of
thermolabile homozygotes, heterozygotes, and non-
thermolabile homozygotes were 11.5, 43.7, and
44.8% respectively (in close agreement with the
Hardy-Weinberg prediction of 11.1, 44.5, and
44.4%: £ test p > 0.5).
Thermolabile homozygous individuals had mean
homocysteine levels significantly higher than those
of heterozygotes, whose homocysteine levels were
slightly, but not significantly, higher than those of
non-thermolabile homozygotes (Table 1). To assess
the genotype/phenotype relationship we divided the
population into tenths according to homocysteine
ranking (Table 2). The thermolabile homozygote fre-
quency exhibited a gradual increase from 1.6% in
Table 1 Plasma homocysteine, serum folate and vitamin B12 levels by MTHFR genotype
Genotype
(n = 72) = 273) = 280)
Significance
Mean homocysteine (u.mol/1)
Mean homocysteine in
men with folate
below median (u.mol/1)
Mean homocysteine in
men with folate
above median (u.mol/1)
Mean serum folate
(nmol/l)
Mean vitamin B12
(pmol/l)
9.46(8.40,10.65)
11.22(9.57,13.16)
(n = 46)
6.82(6.21,7.49)
(n = 24)
9.29(8.33,10.35)
221(198,248)
7.12(6.85,7.40)
7.88(7.47,8.31)
(n=134)
6.54(6.23,6.87)
(n = 133)
10.76(10.26,11.29)
259(247,272)
6.77(6.55,7.01)
7.43(7.02,7.86)
(n=118)
6.32(6.08,6.57)
(n=156)
12.31(11.71,12.93)
266(253,279)
Geometric mean values of homocysteine, folate, and vitamin B12 are shown with 95% CIs (in brackets) for thermolabile
homozygotes ( + / + ) , heterozygotes (+/—), and non-thermolabile homozygotes (—/—). Mean homocysteine levels for
men whose serum folate levels are above and below the median value (11.04 nmol/l) show that the association of high
homocysteine with the + / + genotype is highly dependent on folate status. * Significant difference (p<0.003) between
the + / + genotype and the other two genotypes; **AII three genotypes are significantly different from each other
(p<0.001). Note: folate levels measured for 611 subjects.
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Table 2 MTHFR genotypes
Homocysteine ranking
by tenth
Percentage of each
genotype within
each tenth
in
-h
(n)
-h
(n)
—t
(n)
relation to
1
/ + 35.5
(22)
1- 40.3
(25)
/ - 24.2
(15)
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homocysteine concentration
2
11.3
(7)
43.5
(27)
45.2
(28)
3
18.8
(12)
50.0
(32)
31.3
(20)
4
8.2
(5)
50.8
(3D
41.0
(25)
5
6.3
(4)
50.8
(32)
42.9
(27)
6
9.5
(6)
31.7
(20)
58.7
(37)
7
11.3
(7)
40.3
(25)
48.4
(30)
8
6.3
(4)
41.3
(26)
52.4
(33)
9
6.3
(4)
42.9
(27)
50.8
(32)
10
1.6
(1)
45.2
(28)
53.2
(33)
Individuals were assigned to tenths according to their homocysteine ranking: tenth 1 corresponds to highest homocysteine
levels. The percentage of individuals within each tenth who are thermolabile homozygotes ( + / + ), heterozygotes ( + /—) ,
and non-thermolabile homozygotes {—/—) is shown.
the lowest tenth, to between 1 0 % and 2 0 % in the
second and third highest tenths. In the upper tenth,
the percentage of homozygotes rose appreciably to
35.5%, but there was a striking further increase in
the frequency of thermolabi le homozygotes among
the individuals w i th the highest homocysteine rank-
ings w i th in this group. We therefore sequentially
subdivided the upper tenth, and observed progressive
increases in thermolabi le homozygote frequency as
the numbers of individuals were progressively
restricted according to their ranking, i.e. 11 of the
top 20 (55%), and 7 of the top 10 (70%). We
calculated the relative risk of being in the top 5, 10,
20 and 5 0 % of the populat ion wi th respect to
homocysteine for individuals wi th the thermolabi le
homozygous genotype relative to non-thermolabi le
homozygotes and to non-thermolabi le homozygotes
and heterozygotes combined (Table 3). There was a
highly significant 9.7-fold risk of being in the top
5% for thermolabi le homozygotes relative to non-
thermolabi le homozygotes. This risk was slightly less
(7.2-fold) when thermolabi le homozygotes were
compared w i th non-thermolabi le homozygotes and
heterozygotes together. A small risk was observed
for heterozygotes relative to non-thermolabi le homo-
zygotes, but this was only statistically significant in
the upper 5 0 % of the homocysteine distr ibution
considered as a who le . Overal l the data point to a
small but significant thermolabi le heterozygote effect
in elevating homocysteine, wh ich has not been
reported previously.
When serum folate status was taken into account,
the relationship between the homozygous thermola-
bi le genotype and homocysteine levels was restricted
to those individuals whose serum folate levels were
below the median value ( p < 0 . 0 0 1 ) . In individuals
wi th folate levels above the median value, homocyst-
eine levels d id not vary significantly between geno-
types ( p = 0.3) (Table 1).
Serum folate and vi tamin B12 levels were both
inversely related to homocysteine levels (Figure 2),
and also correlated w i th each other (not shown). We
observed a relationship between serum folate con-
centration and MTHFR genotype w i th homozygous
thermolabi le individuals having the lowest serum
folate levels and non-thermolabi le homozygotes the
highest (Table 1). Heterozygotes had intermediate
serum folate levels. The differences in folate levels
between all three genotypes were significant
( p < 0 . 0 0 1 ) . Vi tamin B12 levels were also signific-
antly lower in thermolabi le homozygotes than in
individuals w i th other genotypes (Table 1). The differ-
ences in folate and B12 levels between genotypes
for each adjacent tenth were not statistically signific-
ant due to the small numbers of thermolabi le homo-
zygotes involved, but the trend is apparent,
Table 3 The relative risk of mild hyperhomocysteinaemia conferred by MTHFR thermolabile genotypes
Homocysteine
rank
Top 5%
Top 10%
Top 20%
Top 50%
+/ +
Risk
9.72
5.70
2.62
1.69
relative to —/—
95% Cl
(3.91,24.17)
(3.12,10.42)
(1.77,3.89)
(1.37,2.08)
P
< 0.001
< 0.001
< 0.001
< 0.001
+/ +
Risk
7.20
4.22
2.34
1.47
relative to (+ /—
95% Cl
(3.72,13.93)
(2.67,6.88)
(1.68,3.28)
(1.23,1.75)
and - / - )
P
< 0.001
< 0.001
< 0.001
< 0.001
+ /-
Risk
1.71
1.71
1.24
1.31
relative to —/—
95% Cl
(0.63,4.64)
(0.92,3.17)
(0.86,1.79)
(1.10,1.57)
P
0.29
0.08
0.25
0.003
Relative risks of being in the top 5, 10, 20 and 50% of the homocysteine distribution for individuals with the thermolabile
homozygous genotype ( + / + ) relative to non-thermolabile homozygotes (—/—), and to non-thermolabile homozygotes
and heterozygotes combined, and for thermolabile heterozygotes ( + / — ) relative to non-thermolabile homozygotes.
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Figure 2. The relationship between a serum folate and
b vitamin B12 levels and homocysteine. Mean log levels
are plotted separately for each genotype within the homo-
cysteine distribution (homocysteine decreases from tenth 1
to 10). Thermolabile homozygotes, filled squares; hetero-
zygotes, open triangles; non-thermolabile homozygotes,
open circles. The low B12 value for the homozygous
thermolabile genotype in tenth 10 is due to the presence
of only one such individual in this tenth.
particularly for serum folate in individuals in the
upper half of the homocysteine distribution
(Figure 2a).
We further examined the serum folate and
vitamin B12 levels in the 20 individuals with the
highest homocysteine levels. Most of these indi-
viduals had folate and B12 levels at the low end of
the overall range. Consistent with the genotype/folate
interaction already discussed, on average the thermo-
labile homozygotes had lower folate levels (mean
5.45 nmol/l, n = 11), than individuals with the other
two genotypes (combined mean 7.71 nmol/l, n = 9).
Vitamin B12 levels showed a similar trend. Some
individuals in the top 20 are not thermolabile homo-
zygotes and do not have marked deficiency of folate
or vitamin B12, suggesting the existence of other,
possibly genetic, factors influencing homocysteine
levels.
Discussion
We have shown that in a working male population
homozygosity for the thermolabile MTHFR genotype
is a major contributing factor to mild hyperhomocys-
teinaemia, and in particular to homocysteine levels
above the 95th percentile. The approximately five-
fold increase in frequency of the thermolabile geno-
type in the top 5% of the population (to 48%)
relative to its frequency in the bottom 80% is of
particular note because one of the largest studies of
the association of homocysteine with myocardial
infarction (Ml)—a prospective study of 14 916 physi-
cians of whom 271 developed Ml—suggested that
the 95th percentile of homocysteine distribution was
the point at which the risk of Ml increased approxi-
mately three-fold.1
Dietary deficiency of the vitamin cofactors B6
(for CBS) and B12 (for methionine synthase), and of
folic acid, the precursor of the methyl donor
5-methyltetrahydrofolate, can all cause elevated
homocysteine levels, although evidence that this is
a major contributing factor to hyperhomocysteinae-
mia only exists for an elderly population studied by
Selhub et al.24 (who estimated that up to 2/3 of
hyperhomocysteinaemic 67-96 year olds from the
Framingham Heart Study had elevated homocysteine
attributable to deficiency of one of these three dietary
components).
Our study identifies two separate aspects of the
interaction between the homozygous thermolabile
MTHFR genotype and folate metabolism.
Firstly, in individuals with serum folate levels
below the median, those with the homozygous
thermolabile genotype have higher homocysteine
levels (50% higher than non-thermolabile homozy-
gotes). Heterozygotes show a smaller increase (6%)
in homocysteine relative to individuals with no
thermolabile allele. Among individuals whose folate
levels are above the median, the homozygous ther-
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molabile genotype does not appear to affect homo-
cysteine levels. Jacques ef al. recently observed a
similar effect in thermolabile homozygotes (but not
heterozygotes) with folate levels below the median.25
The folate level below which the thermolabile
homozygous genotype becomes a homocysteine-
determining factor has yet to be established. However
it is apparent that low folate has a particularly
detrimental effect on the capacity of thermolabile
homozygotes to remethylate homocysteine.
Secondly, the thermolabile homozygotes as a
group have significantly lower serum folate levels
than the other genotypes, indicating that the thermo-
labile homozygous genotype itself causes reduced
serum folate levels. It seems likely that the above
two interactions between genotype and folate can
act in concert to produce the mild hyperhomocystei-
naemic phenotype.
The apparently causal relationship between geno-
type and serum folate levels indicates that in a
proportion of individuals in the higher homocysteine
range the lower folate levels are not necessarily
attributable to dietary insufficiency alone but are, at
least in part, a direct result of the reduced activity
of the thermolabile enzyme. In a recent study of
women with multiple NTD events, Lucock et al.26
have proposed that the low levels of plasma
5-methyltetrahydrofolate (measured specifically by
HPLC) relative to dietary folate intake observed in
such cases, may reflect an underlying control or
structural defect in the MTHFR gene or in another
gene involved in an earlier step in the conversion of
dietary folate to 5-methyltetrahydrofolate. They
speculated that such cases may need a higher intake
of dietary folate (or supplements) to achieve the
same plasma 5-methyltetrahydrofolate concentrations
as controls. In a subsequent study decreased serum
folate levels and elevated red-cell folate levels were
observed in thermolabile homozygotes by van der
Put ef a/.21 who point out that the MTHFR enzyme
product 5-methyltetrahydrofolate is the predominant
form of folate in serum, while other folate species
including the substrate 5,10-methylenetetrahydro-
folate are mainly present in cells.
In conclusion, it appears that homozygosity for
the MTHFR thermolabile mutation is a major cause
of mild hyperhomocysteinaemia in the study popula-
tion. The frequency of the mutation may be expected
to vary between populations, and this may account
for some of the variation in homocysteine levels
observed in different countries and regions (Malinow
et al., submitted). The extent to which this is due to
variations in MTHFR genotype frequencies will not
become clear until significant numbers of individuals
from defined populations have been studied.
Dietary supplementation with folic acid given
periconceptionally has already been shown to be
effective in the reduction of NTDs,27'28 some of
which are caused by the thermolabile MTHFR
allele.20'21 Studies of dietary folic acid
supplementation of healthy individuals and vascular
disease patients indicate that this is a safe and
effective method of reducing homocysteine levels
(provided B12 is not deficient).29"31 It is likely that
extra dietary folic acid can compensate for the
suboptimal function of the thermolabile form of
MTHFR and can therefore be used to reduce the
high homocysteine levels observed in many thermo-
labile homozygotes, thus eliminating this major risk
factor for vascular and thrombotic disease. Our
results establish that for a given homocysteine con-
centration thermolabile MTHFR homozygotes have
lower serum folate levels, indicating that there is a
direct genotype—folate interaction. We suggest that
the thermolabile MTHFR genotype should be taken
into account in the design of studies aiming to
identify the optimum dose of folic acid required to
lower homocysteine concentration, as the effect-
iveness of folate supplementation is likely to vary
with genotype.
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